Back to News
Oct 15, 2025 4:00 PM

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

JNJ is trading at elevated levels. See what the experts say here.

Johnson & Johnson also announced plans to separate its Orthopedics business to enhance strategic and operational focus.

The transaction would establish a standalone orthopedics business, operating as DePuy Synthes. Johnson & Johnson aims to complete the project within 18 to 24 months.

Also Read: FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

Analyst ...